What happenedOn March 25, 2026, the FDA approved Avlayah (tividenofusp alfa-eknm) for the treatment of neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients
The denosumab biosimilar market has gone from quiet anticipation to a full sprint. In the past twelve months, the FDA has approved nine pairs of
Immunoglobulin (IG) has long been a specialized area within pharmacy, yet it continues to influence the broader market. As such, it’s important for pharmaceutical professionals
Yeah, Yeah….The message from the article below is preaching to the choir… but this hymn can’t be sung enough. The central message in this article
The FDA recently approved a new ORAL therapy, Jascayd (nerandomilast) from Boehringer Ingelheim, indicated for idiopathic pulmonary fibrosis (IPF) in adult patients. IPF is a
We’ve often written about white bagging, but today’s spotlight article bears yet another look. A recent NASP survey reinforces what many in specialty pharmacy already know:
The FDA recently approved a ‘2fer’, two biosimilars for the same reference therapy. The two in question are Bosaya and Aukelso, denosumab biosimilars for all indications
Amid what some would call chaos in the halls of the FDA, HHS, etc., some light came shining through recently. The FDA announced a new
Cigna’s Evernorth Health Services is making a bold move in the specialty pharmacy space with a $3.5 billion investment in Shields Health Solutions. The deal
The FDA recently approved a new sub-q therapy, Dawnzera (donidalorsen) from Ionis Pharmaceuticals, Inc. indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in
